Bicara Therapeutics Inc
BCAXHealthcare|Biotechnology|USA
$28.88
-0.77 (-2.59%)
Tangible Book
$7.84
About
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Stock Price
+191.1%(1Y)
Pipeline Summary
5 total trials2
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
NOT_YET_RECRUITING: 2Recruiting: 3
Active Trials (3)
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
NCT07465276Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Recruiting
Enrollment: 32 participants
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542Head and Neck Squamous Cell Carcinoma
Phase 1Recruiting
Enrollment: 292 participants
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2Phase 3Recruiting
Enrollment: 650 participants
BioScore
4.8/10
Cautious
Ownership
Recent Insider Trades
Cohlhepp RyanSELL
2026-07-0928,750 shares @ $28.98
Hyep IvanSELL
2026-07-0828,000 shares @ $28.85
Hyep IvanSELL
2026-05-219,200 shares @ $20.42
Mazumdar ClaireSELL
2026-05-1815,000 shares @ $20.04
Cohlhepp RyanSELL
2026-05-1512,500 shares @ $20.29
Data last updated: Jul 13, 2026, 12:45 PM